Exchange Capital Management Inc. lifted its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 4.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,352 shares of the medical research company’s stock after purchasing an additional 1,204 shares during the quarter. Amgen makes up about 1.4% of Exchange Capital Management Inc.’s holdings, making the stock its 23rd biggest position. Exchange Capital Management Inc.’s holdings in Amgen were worth $5,006,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Commonwealth Bank of Australia grew its stake in Amgen by 19.7% in the 4th quarter. Commonwealth Bank of Australia now owns 66,961 shares of the medical research company’s stock valued at $13,027,000 after buying an additional 11,040 shares during the last quarter. UNIVEST FINANCIAL Corp grew its stake in Amgen by 1.5% in the 4th quarter. UNIVEST FINANCIAL Corp now owns 23,544 shares of the medical research company’s stock valued at $4,583,000 after buying an additional 355 shares during the last quarter. Phocas Financial Corp. acquired a new position in Amgen in the 4th quarter valued at $117,000. Duality Advisers LP acquired a new position in Amgen in the 4th quarter valued at $3,983,000. Finally, Congress Asset Management Co. MA boosted its holdings in Amgen by 0.8% in the 4th quarter. Congress Asset Management Co. MA now owns 40,627 shares of the medical research company’s stock valued at $7,909,000 after purchasing an additional 311 shares during the period. Institutional investors own 80.65% of the company’s stock.

In other news, Director Ronald D. Sugar sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $193.18, for a total transaction of $386,360.00. Following the completion of the transaction, the director now directly owns 15,092 shares of the company’s stock, valued at approximately $2,915,472.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 6,000 shares of company stock valued at $1,115,580 over the last ninety days. 0.25% of the stock is owned by insiders.

A number of brokerages have weighed in on AMGN. Oppenheimer set a $224.00 price target on shares of Amgen and gave the company a “buy” rating in a report on Sunday, January 27th. Mizuho reissued a “buy” rating and issued a $211.00 price target on shares of Amgen in a report on Tuesday, February 26th. JPMorgan Chase & Co. reissued a “hold” rating and issued a $190.00 price target on shares of Amgen in a report on Wednesday, May 15th. BidaskClub downgraded shares of Amgen from a “buy” rating to a “hold” rating in a report on Wednesday, February 20th. Finally, Zacks Investment Research downgraded shares of Amgen from a “buy” rating to a “hold” rating in a report on Wednesday, January 23rd. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $208.84.

NASDAQ:AMGN opened at $169.91 on Monday. The stock has a market cap of $103.63 billion, a PE ratio of 11.80, a price-to-earnings-growth ratio of 2.24 and a beta of 1.15. Amgen, Inc. has a 52 week low of $166.30 and a 52 week high of $210.19. The company has a quick ratio of 2.53, a current ratio of 2.77 and a debt-to-equity ratio of 2.71.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, April 30th. The medical research company reported $3.56 EPS for the quarter, topping analysts’ consensus estimates of $3.45 by $0.11. The company had revenue of $5.56 billion during the quarter, compared to the consensus estimate of $5.55 billion. Amgen had a net margin of 34.00% and a return on equity of 71.02%. The firm’s revenue for the quarter was up .1% compared to the same quarter last year. During the same period last year, the firm earned $3.47 EPS. On average, equities research analysts expect that Amgen, Inc. will post 13.94 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a dividend of $1.45 per share. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.41%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s payout ratio is 40.28%.

TRADEMARK VIOLATION WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2019/05/20/exchange-capital-management-inc-has-5-01-million-stake-in-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Read More: Cost of Capital Explained

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.